Chemoreflex sensitization produced by chronic intermittent hypoxia in rats is attenuated by angiotensin II type 1 receptor (AT 1 R) blockade. Both AT 1 R blockade and xanthine oxidase inhibition ameliorate chronic intermittent hypoxia-induced endothelial dysfunction. We hypothesized that treatment with losartan and allopurinol would reduce chemoreflex sensitivity and improve hypoxic vasodilatation in patients with obstructive sleep apnoea. Eighty-six hypertensive patients with apnoea-hypopnoea index ≥25 events h −1 and no other cardiovascular, pulmonary, renal or metabolic disease were randomly assigned to receive allopurinol, losartan or placebo for 6 weeks. Treatment with other medications and/or continuous positive airway pressure remained unchanged. Tests of chemoreflex sensitivity and hypoxic vasodilatation were performed during wakefulness before and after treatment. Ventilation (pneumotachography), muscle sympathetic nerve activity (microneurography), heart rate (electrocardiography), arterial oxygen saturation (pulse oximetry), blood pressure (sphygmomanometry), forearm blood flow (venous occlusion plethysmography) and cerebral flow velocity (transcranial Doppler ultrasound) were measured during eupnoeic breathing and graded reductions in inspired O 2 tension. Losartan and allopurinol lowered arterial pressure measured during eupnoeic breathing and exposure to acute hypoxia.
INTRODUCTION
Chemoreflex sensitivity is enhanced after exposure to chronic intermittent hypoxia (CIH) in experimental animals (Del Rio, Andrade, Lucero, Arias, & Iturriaga, 2016; Marcus, Li, Bird, Schultz, & Morgan, 2010; Morgan, Adrian, Wang, Bates, & Dopp, 2016a; Prabhakar, Peng, Kumar, & Nanduri, 2015) , healthy humans (Pialoux et al., 2009; Tamisier et al., 2011) and humans with obstructive sleep apnoea c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society (OSA; Mansukhani, Wang, & Somers, 2015; Narkiewicz et al., 1999) .
Increased generation of reactive oxygen species, such as superoxide, is thought to make an important contribution to this sensitization (Del Rio, Moya, & Iturriaga, 2010; Lim et al., 2015; Morgan, Bates, Rio, Wang, & Dopp, 2016b; Pialoux et al., 2009; . Potential sources of superoxide ion in the carotid body and other components of the extended chemoreflex arc include angiotensin II and xanthine oxidase.
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New Findings
• What is the central question of this study?
In sleep apnoea, a putative link between intermittent hypoxia and hypertension is the generation of oxygen radicals by angiotensin II and xanthine oxidase within the chemoreflex arc and vasculature. We tested whether chemoreflex control of sympathetic outflow, hypoxic vasodilatation and blood pressure are altered by angiotensin blockade (losartan) and/or xanthine oxidase inhibition (allopurinol).
• What is the main finding and its importance?
Both drugs lowered blood pressure without altering sympathetic outflow, reducing chemoreflex sensitivity or enhancing hypoxic vasodilatation. Losartan and allopurinol are effective therapies for achieving blood pressure control in sleep apnoea.
In the present study, we sought to determine whether angiotensin II type 1 receptor (AT 1 R) blockade with losartan and/or xanthine oxidase inhibition with allopurinol reduces chemoreflex sensitivity in humans with OSA. Impairments in local vascular regulation have also been described with CIH and OSA (Carlson, Rångemark, & Hedner, 1996; Dopp et al., 2011; El Solh et al., 2006; Phillips, Olson, Morgan, & Lombard, 2004; Reichmuth et al., 2009) . Therefore, another goal was to test the hypothesis that allopurinol and losartan, drugs that prevent CIH-induced endothelial dysfunction in rats (Dopp et al., 2011; Marcus et al., 2012) , alter vasodilatory responses to hypoxia in humans with OSA. Given that chemoreflex hypersensitivity and vascular dysfunction are putative contributors to OSA-associated hypertension (Del Rio, Moya, & Iturriaga, 2014; Fletcher et al., 1992a; Khayat et al., 2018; Prabhakar, 2016) , we evaluated the effects of allopurinol and losartan on blood pressure.
METHODS

Ethical approval
Studies conformed to the standards set by the latest version of the Declaration of Helsinki. All subjects provided written informed consent before participation. The protocol was approved by the University of Wisconsin Health Sciences Institutional Review Board (HS IRB 2012-0036) . Other referral sites deferred oversight to the University of Wisconsin Health Sciences Institutional Review Board.
This research was registered at clinicaltrials.gov (NCT01637623) before recruitment of subjects.
Research design
We conducted a randomized comparison (parallel design; 1:1:1 allocation ratio) of the effects of allopurinol, losartan or placebo on chemoreflex sensitivity, hypoxic vasodilatation and blood pressure.
The primary outcome measure was the muscle sympathetic nerve activity (MSNA) response to acute hypoxic exposure. Secondary outcome measures included hyperoxic inhibition of MSNA and the ventilatory and vasodilatory responses to hypoxia.
Subjects
Male and female subjects, aged 21-65 years, were recruited at four medical centers 
Sample size determination
A priori, we estimated the sample size required for 80% power to detect the difference in MSNA-S aO 2 slopes we previously observed in a pilot study of five patients with untreated OSA and 12 control subjects who were exposed to a progressive hypoxia protocol identical to the one in the present study. This difference was −1.30 versus −0.54 bursts min −1 (% S aO 2 ) −1 or 0.76 slope 'units' . Based on 10,000 trials of simulated data from similar distributions seen from our previous data, we estimated that 40 subjects per arm would be needed for ANOVA with a two-sided level of 0.05. An updated sample size estimate was made based on the differences and standard deviations in the primary outcome variable existing at the time of a 1 year interim analysis. This calculation revealed that we would have 90% power (versus 80% in the original sample size calculation) to find a significant between-group difference at a significance level of 0.017 (Bonferroni-adjusted for three tests) if the trend continued and we had complete MSNA slope data from 20 subjects per group. Apnoeas, hypopnoeas and arousals were scored using American
In-laboratory, overnight polysomnography
Academy of Sleep Medicine guidelines (Berry et al., 2012; Iber, AncoliIsrael, Chesson, & Quan, 2007) . Apnoea-hypopnoea index refers to the number of apnoeas and hypopneas per hour of objectively measured sleep. The respiratory disturbance index was defined as the number of apnoeas, hypopnoeas and respiratory event-related arousals per hour of sleep. The percentage of time with S aO 2 <88% was computed.
Randomization
Eligible subjects were stratified into categories based on their baseline CPAP use ( Figure 1 ). As each subject was assigned to a stratum, a research pharmacist not otherwise involved in the study Nightly Hours of CPAP Use F I G U R E 1 Numbers of subjects allocated to the three treatment groups from the randomization strata. Assignment into a stratum was based on average number of hours of nightly continuous positive airway pressure (CPAP) in the month before study enrolment placed him or her into a treatment group using the next ascending unused randomization number within that stratum. Participants, care
providers, investigators and outcomes assessors were blinded to group assignment. Blinding was maintained by the use of capsules of identical appearance in the three treatment groups. Figure 2 shows the flow of participants through the study.
Cardiorespiratory measurements
We acquired heart rate from the electrocardiogram, S aO 2 by pulse 
Muscle sympathetic nerve activity
Postganglionic MSNA was recorded from the fibular nerve using the technique of Vallbo, Hagbarth, Torebjörk, & Wallin (1979) as previously described (Khayat, Przybylowski, Meyer, Skatrud, & Morgan, 2004) .
Briefly, neural signals were passed to a differential preamplifier, an amplifier (total gain, 100,000), a bandpass filter (700-2000 Hz) and an integrator (time constant, 100 ms). Placement of the recording electrode within a muscle fascicle was confirmed as follows: (i) presence of muscle twitches, but not paresthesias, in response to electrical stimulation; (ii) pulse-synchronous nature of the nerve activity; (iii) appearance of afferent activity in response to tapping or stretching of muscle, but not gentle stroking of skin, in the appropriate receptive fields; and (iv) absence of neural activation in response to arousal stimuli. Once an acceptable nerve recording was obtained, the subject was instructed to maintain the leg in a relaxed position for the duration of the study. Acceptable neurograms were obtained in 79% of subjects at the time of baseline studies. If an acceptable recording was not acquired at baseline, we did not attempt to record nerve traffic at the time of follow-up. In two subjects, an acceptable recording was obtained at the baseline, but not the follow-up, study.
Assessed for eligibililty (139) Randomized (87) Excluded ( (0) Lost to follow-up (0) Discontinued intervention (0) Analyzed (n=30) Excluded from analysis (0) Analyzed (n=28) Excluded from analysis (0) Analyzed (n=28) Excluded from analysis (0) Lost to follow-up (0) Discontinued intervention (0) Lost to followup (2; time constraint) Discontinued intervention (1; rash)
did not meet inclusion criteria (50) unable to schedule chemoreflex tests (2) in all subjects. For purposes of quantification, MSNA was expressed as the burst frequency (in bursts per minute), burst incidence (bursts per 100 heart beats) and total activity (burst frequency × mean burst amplitude).
Physiological assessment protocol
Respiratory and neurocirculatory data were acquired during two tests of chemoreflex function performed during wakefulness, with subjects in the supine position. Testing occurred between 11.00 and 14.00 h, and room temperature was maintained at 21-24 • C. First, chemoreflex-mediated inhibition of MSNA was assessed during four 1 min exposures to hyperoxia (fractional inspired O 2 , 1.0), which were separated by ≥3 min of room air breathing. Fifteen-second averages of MSNA burst frequency and total activity during the 1 min exposure were computed, and a nadir value was determined. The nadir values for the four hyperoxic trials in each subject were then averaged.
Second, chemoreflex-mediated activation of MSNA and ventilation and hypoxic vasodilatation were assessed during a steady-state hypoxia challenge consisting of 3 min of stable room air breathing, followed by three 3 min periods with S aO 2 held constant at 90, 85 and 80%.
Hypoxia was created by supplementation of the inspired air with nitrogen. Carbon dioxide was added to the inspired air, as needed, to maintain P ET,CO 2 at the eupnoeic level. Heart rate and blood pressure responses to hypoxia and hypoxic vasodilatation in the forearm and cerebral circulations were measured during the hypoxic challenge.
During normoxia and graded hypoxia, 3 min averages were computed for all respiratory and neurocirculatory variables.
To determine whether high levels of ventilation produced by hypoxia per se affected MSNA (Narkiewicz et al., 1999; Somers, Mark, Zavala, & Abboud, 1989) , heart rate and blood pressure, subjects completed a 3 min trial of voluntarily controlled breathing in normoxia, with tidal volume and breathing frequency maintained at the highest levels reached during hypoxia. The P ET,CO 2 was maintained at the eupnoeic level. Subjects were assisted in maintaining target levels of tidal volume and frequency by visual and auditory feedback.
Both tests of chemoreflex function, assessment of hypoxic vasodilatation, controlled breathing and polysomnograms were repeated after 6 weeks of drug treatment.
Drug treatment
Subjects received oral treatment with allopurinol (300 mg day −1 ), losartan (50 or 100 mg day −1 ) or placebo for 6 weeks, beginning on the day after baseline assessments of chemoreflex function and hypoxic vasodilatation. Losartan was initiated at 50 mg day −1 and increased to 100 mg day −1 after 2 weeks if blood pressure was >100/60 mmHg.
Adherence to study medications was assessed by pill count.
Data analysis
Chemoreflex responses to hypoxia were quantified by computing slopes of the linear relationships between ventilatory and neurocirculatory variables with S aO 2 . During the initial visit, one subject reported feeling panicky when S aO 2 was 90% and could not complete the hypoxia trial. Data points for this subject were deemed outliers, with values up to 9 SD away from the means for the other subjects. At follow-up, this subject was asked to complete an abbreviated test (normoxia and 90% S aO 2 only) and did not report symptoms of panic. The outlying data for this subject were handled statistically by imputing MSNA and ventilatory data based on mean values from the other losartan subjects. A sensitivity analysis was completed based on collected data and imputed data, with no major differences in hypothesis testing results. 
Statistics
R version 3.3.1 statistical software (R Foundation for Statistical
Computing, Vienna, Austria) was used. Between-group comparison of baseline characteristics was conducted with ANOVA or 2 tests.
Between-group comparisons of changes over time were conducted using repeated-measures ANOVA (RM-ANOVA), with group, time and group-by-time interaction as fixed effects, and subject as a random effect. This analysis was performed with and without controlling for CPAP use, measured as average nightly use in minutes, as a covariate.
If both methods resulted in similar conclusions, only results obtained with CPAP adherence as a covariate are reported. Post hoc two-way comparisons were conducted using Tukey's adjustment for familywise testing. All analyses were done according to the intent-to-treat principle. 'On-protocol' analyses yielded similar conclusions; therefore, only results of intent-to-treat analyses are reported. Given that sex differences have been observed in chemoreflex sensitivity (Lozo, Komnenov, Badr, & Mateika, 2017) , hypoxic vasodilatation (Casey, Shepherd, & Joyner, 2014) and sympathetic regulation of vascular tone (Hinojosa-Laborde, Chapa, Lange, & Haywood, 1999) , the possibility of differential sex-specific effects was examined using an exploratory analysis, adjusted for CPAP adherence.
RESULTS
Participation was terminated after the initial visit in one subject because of excessive blood pressure and in another owing to scalp rash. Two other subjects voluntarily withdrew after the initial visit owing to time constraints. All four subjects had been randomized to receive placebo. Following the intent-to-treat principle, data collected from these subjects are included in the analyses. One subject who had been allocated to the losartan group did not participate in physiological assessments and did not receive the intervention secondary to ECG abnormalities detected at the initial visit.
Subject characteristics before and after interventions were comparable in the three groups ( groups.
The CPAP pressures, adherence and residual apnoea-hypopnoea indices did not differ among groups and remained stable throughout the trial (Table 2 ). Adherence to study medications, assessed by pill counts, did not differ among groups [97 ± 8 (SD), 99 ± 3 and 97 ± 5%
in allopurinol-, losartan-and placebo-treated subjects, respectively].
The percentages of subjects taking antihypertensive medications in the allopurinol, losartan and placebo groups, respectively, were as follows: diuretics, 33, 29 and 4%; -adrenergic blockers, 23, 11 and 14%; and calcium channel blockers, 13, 7 and 4%. The types and doses of concomitant antihypertensive agents did not change during the study.
Drug treatment and baseline (normoxic) cardiorespiratory values (Table 3)
Before treatment initiation, all values were comparable in the three groups. After 6 weeks of treatment, MAP in normoxia before chemoreflex testing was significantly reduced in the losartan and allopurinol groups, whereas it remained stable in placebo subjects. The blood pressure-lowering effect of losartan was greater than that of allopurinol. Figure 3 , where the 95% confidence intervals for these variables do not contain zero.
TA B L E 1 Subject characteristics by randomized group at baseline and after interventions
Charateristic Allopurinol (n = 30) Losartan (n = 28) Placebo (n = 28) P value 
Data shown are the mean (SD), median (interquartile range) or n (%). RM-ANOVA revealed no statistically significant differences for group-by-time interaction. * P value for between-group comparison at each time point. † P value for group-by-time interaction, adjusted for average daily continuous positive airway pressure use (in minutes). ‡ Postintervention measurements were not obtained (these were inclusion criteria).
Drug treatment and chemoreflex responsiveness (Table 4)
Acute exposure to hypoxia resulted in brisk, progressive increases inV E , caused mainly by increases in V T . There were no betweengroup differences in the relationships betweenV E or its components and S aO 2 at either time point. Treatment-related changes inV E -S aO 2 relationships did not differ among groups.
Acute exposure to graded hypoxia produced progressive sympathetic activation. We observed no between-group differences in the slopes of MSNA-S aO 2 relationships, either at the initial visit or after drug treatment. Treatment-related changes in MSNA slopes did not differ among groups.
Exposure to hyperoxia resulted in a rapid rise in P 
Haemodynamic responses to acute hypoxia (Table 4)
Hypoxia elicited modest increases in MAP and heart rate. We observed no between-group differences in the slopes of the MAP or heart rate responses to hypoxia, either at the initial visit or after drug treatment. In the forearm and cerebral circulations, acute hypoxic exposure produced vasodilatation. Treatment-related changes in hypoxic vasodilatation did not differ among groups.
Influence of hyperpnoea on MSNA
When subjects voluntarily reproduced, in normoxia, the same elevated levels of ventilation elicited by reduction of S aO 2 to 80%, MSNA was the same as during eupnoea (RM-ANOVA P > 0.05; Figure 5 ). Likewise, neither heart rate nor MAP differed in voluntary hyperpnoea versus eupnoea (data not shown).
TA B L E 2 Continuous positive airway pressure (CPAP) treatment parameters in the randomized groups before the initial and final visits
Gender subgroup analysis
Allopurinol-and losartan-induced reductions in baseline MAP were present in both male (RM-ANOVA P = 0.001) and female (RM-ANOVA P = 0.050) subjects. An absence of effects of treatment on baseline ventilation, heart rate and MSNA was observed in both males and females (data not shown). In females, baseline FVC increased significantly with allopurinol, whereas it remained stable in losartanand placebo-treated females (RM-ANOVA P = 0.009; Figure 6 ).
Baseline FVC in males was not affected by any treatment (RM-ANOVA P = 0.248). Baseline CVC did not differ among groups, either in males or in females ( Figure 6 ). No sex effects were noted in chemoreflex sensitivity or hypoxic vasodilatation (data not shown).
DISCUSSION
We evaluated the effects of xanthine oxidase inhibition with allopurinol and angiotensin II receptor antagonism with losartan on respiratory and neurocirculatory function in hypertensive patients with moderate-to-severe OSA. The major finding is that both drugs significantly lowered blood pressure during normoxic, eupnoeic breathing and during acute exposure to hypoxia without reducing sympathetic vasoconstrictor activity. In contrast to our hypotheses, based on previous findings in rats exposed to CIH (Dopp et al., 2011; Marcus et al., 2010 Marcus et al., , 2012 Morgan et al., 2016a, b) , the slopes of the chemoreflex and vasodilatory responses to acute hypoxia were not altered by losartan or allopurinol.
Insufficient statistical power is an unlikely explanation for our negative findings regarding chemoreflex responsivity. A priori, we established a 'clinically relevant difference' for the MSNA-S aO 2 relationship (0.76 slope 'units') by calculating the difference in slope between patients with untreated OSA and healthy control subjects in a pilot study. In the present study, 95% confidence intervals surrounding the change in MSNA slope were sufficiently narrow (∼±0.31) to detect a difference of this magnitude, had one existed. We considered the possibility that augmented hypoxic ventilatory drive obscured treatment-related changes in the sympathoexcitatory response, via the sympatholytic effect proposed by previous investigators (Narkiewicz et al., 1999; Somers et al., 1989) ; however, none of the treatments altered hypoxic ventilatory responses. Moreover, we found no evidence of sympathetic inhibition when subjects voluntarily mimicked, in normoxia, the same high levels of ventilation elicited by acute hypoxia, either before or after drug treatment ( Figure 5 ). In the present subjects, sympathetic burst frequency and incidence were lower in control conditions than in untreated OSA patients previously described and, in fact, were comparable in magnitude to values reported for control subjects without OSA (Carlson et al., 1993; Donadio et al., 2007; Goya et al., 2016; Grassi et al., 2014; Henderson et al., 2016; Imadojemu et al., 2007; Narkiewicz et al., 1999; Waradekar, Sinoway, Zwillich, & Leuenberger, 1996) . Excessive daytime sleepiness, which is associated with sympathetic hyperactivity (Donadio et al., 2007) and cardiovascular morbidity (Feng, He, Zhang, & Chen, 2012) in patients with OSA, was absent in the majority of our subjects. We suspect that the stringent exclusion criteria used to minimize effects of co-morbid conditions, along with concurrent CPAP usage, resulted in a relatively healthy cohort with normal chemoreflex responsiveness. For ethical reasons, we did not ask our subjects to delay or discontinue CPAP treatment for the duration of the study. Instead, we requested that subjects maintain customary CPAP use patterns during participation. Adherence to CPAP was relatively high (5.6 h night −1 ) and was indeed stable over the study period. Continued effectiveness of clinically recommended pressure settings was demonstrated by low and stable residual apnoea-hypopnoea indices (Table 2) . Concurrent CPAP usage resulted in nightly intermittent hypoxia exposures substantially lower than those suggested by the subjects' pre-CPAP apnoea-hypopnoea indices. Therefore, concurrent CPAP usage allowed by our experimental design might have obscured the beneficial effects we were seeking. Nevertheless, our design allowed us to evaluate the cardiorespiratory effects of the drugs in a common clinical scenario, i.e. partial night CPAP use, where some intermittent hypoxia episodes remain untreated (Weaver & Grunstein, 2008 ).
TA B L E 3 Baseline (normoxic) values measured before graded hypoxia exposure at initial and final visits
Chronic intermittent hypoxia in rodents as a model for human sleep apnoea
Perhaps the positive effects of losartan and allopurinol on chemosensitivity and hypoxic vasodilatation we previously demonstrated in CIH-exposed rats were not observed in this group of human subjects simply because CIH is a poor model for OSA. It is certainly true that the model fails to mimic all aspects of OSA (e.g. no upper airway occlusion, no concurrent hypercapnia and no sleep disruption); nevertheless, our CIH protocol features a temporal pattern of cyclical decreases in S aO 2 (i.e. slow desaturations followed by rapid resaturations) that is 'human like' (Lim et al., 2015; Morgan et al., 2016a, b) . Moreover, our CIH protocol is a good model for the cardiorespiratory consequences OSA, because both produce diurnal increases in arterial pressure (Becker et al., 2003; Fletcher, Lesske, Qian, Miller, & Unger, 1992b; Marcus, Olson, Bird, Philippi, & Morgan, 2009 ), sympathetic activation (Carlson et al., 1993; Marcus et al., 2010) , impaired endotheliumdependent vasodilatation (Carlson et al., 1996; Phillips et al., 2004) , increased arterial stiffness (Phillips, Hedner, Berend, & Grunstein, 2005; Phillips, Olson, Lombard, & Morgan, 2006) , and evidence of oxidative stress (Lavie, 2015; Morgan et al., 2016b) . Accordingly, we believe that hypotheses based on our rat data were not upheld in humans, not because of a failure of the model per se, but rather because the total daily 'dose' of intermittent hypoxia in our rat model was more severe than in our human subjects, leading to more pronounced ventilatory and neurocirculatory impairments. Our rats were exposed to CIH for 10-12 h day −1 (15 events h −1 ), whereas the majority of our human subjects were adequately treated with CPAP (5-6 h of CPAP use per night; residual apnoea-hypopnoea index, 2-3 events h −1 ). In our previous rat studies, allopurinol and losartan, which were administered before and during exposure to CIH, were observed to prevent chemoreflex sensitization and impaired vascular function. In the present human study, we investigated the ability of these agents to reverse OSA-induced abnormalities in cardio- 
F I G U R E 3
Observed changes in baseline values for primary and secondary outcome measures (mean, 95% confidence interval) in the three treatment groups. Mean arterial pressure was reduced, relative to placebo, with allopurinol and losartan treatments. The reduction produced by allopurinol was smaller than that caused by losartan. No statistically significant differences in other variables were observed. The FVC and CVC values were multiplied by 100, and ventilation values were multiplied by 10, so that the data points are discernable on these axes. Abbreviations: CVC, cerebral vascular conductance; FVC, forearm vascular conductance; MAP, mean arterial pressure; and MSNA, muscle sympathetic nerve activity. * P < 0.05, group-by-time interaction. Pairwise comparisons with Holm adjustment: x P < 0.05, allopurinol versus losartan; y P < 0.05, allopurinol versus placebo; and z P < 0.05, losartan versus placebo
Mechanisms of chemoreflex hypersensitivity caused by intermittent hypoxia
We previously demonstrated that chemoreflex hypersensitivity caused by CIH in rats is dependent on AT 1 R signalling in the carotid body (Marcus et al., 2010) . In CIH-exposed pheochromocytoma cells, xanthine oxidase is a crucial component of reactive oxygen speciesgenerating pathways that activate hypoxia-inducible factor-1 and degrade hypoxia-inducible factor-2 (Nanduri et al., 2013 . If xanthine oxidase were to play an analogous role in carotid body, it could be another important determinant of chemoreflex sensitivity.
The present observations in humans with OSA do not provide support for these notions, however, because neither treatment (AT 1 R blockade nor xanthine oxidase inhibition) altered chemoreflex control of ventilation or sympathetic vasoconstrictor outflow. We would like to emphasize, however, that marked chemoreflex hyperresponsiveness was not present in our hypertensive, but otherwise healthy, OSA patients. Data shown are the mean (SD). Abbreviations: CVC, cerebral vascular conductance; f R , breathing frequency; FVC, forearm vascular conductance; MAP, mean arterial pressure; MSNA, muscle sympathetic nerve activity;V E , minute ventilation; V T , tidal volume; and V T /t I , tidal volume:inspiratory time ratio. * P value for between-group comparison at each time point. † P value for group-by-time interaction, adjusted for average daily continuous positive airway pressure use (in minutes).
TA B L E 4 Slopes (absolute values) of neurocirculatory and ventilatory responses to graded hypoxia at initial and final visits
V E [l min −1 (% S aO 2 ) −1 ] Initial −
Allopurinol and losartan contribute to blood pressure control in patients with OSA
Despite the absence of effects of treatment on chemoreflex and vascular responses to hypoxia, our treatments significantly reduced blood pressure. Average values for systolic pressure in both groups were reduced from the 'stage 1 hypertension' to the 'elevated'
category, as defined in recent guidelines (Whelton et al., 2018) , with greater reductions in the losartan than in the allopurinol group.
Average diastolic pressure, which was not elevated at baseline in either group, was reduced relative to placebo only by losartan.
Antihypertensive effects of losartan (Thunström, Manhem, Rosengren, & Peker, 2016) and valsartan (Pépin et al., 2010) in patients with OSA have been reported previously. In the present losartan-treated subjects, 68% of whom received 100 mg day −1 , changes in blood pressure were comparable to those produced by 160 mg day −1 valsartan (Pépin et al., 2010) and slightly larger than those seen with 50 mg day −1 losartan (Thunström et al., 2016) . Our study extends the previous findings via inclusion of a placebo-treated control group and by demonstrating a potent antihypertensive effect of allopurinol.
Allopurinol decreases blood pressure in patients with hyperuricaemia, essential hypertension and chronic kidney disease (Feig, Soletsky, & Johnson, 2008; Qu, Jiang, & Chen, 2017; Satirapoj, Wirajit, Burata, Supasyndh, & Ruangkanchanasetr, 2015) ; however, an antihypertensive effect of allopurinol has not been demonstrated in OSA.
The mechanism of this effect in our subjects is unlikely to be a reduction in sympathetic tone, because MSNA was not affected by 
Losartan-induced blood pressure lowering and increased MSNA
In losartan-treated subjects, baseline MSNA burst frequency increased by ∼33%, which is more than twice the size of the previously reported day-to-day variability in this measurement (Vallbo et al., 1979 ). An analogous effect of eprosartan was observed in young healthy males (Heusser, Vitkovsky, Raasch, Schmieder, & Schobel, 2003) ; however, losartan either decreased (Béchir, Normoxic eupnoea Hypoxia (SaO2, 80%) Normoxic hyperpnoea F I G U R E 5 Tidal volume (V T ) and muscle sympathetic nerve activity (MSNA) during normoxia, hypoxia (arterial O 2 saturation 80%), and when subjects voluntarily mimicked, in normoxia, the same levels of V T and breathing frequency elicited by the hypoxic exposure. The MSNA was comparable during normoxic eupnoea and normoxic hyperpnoea, indicating that increased ventilatory volumes and rates (not shown), per se, have no effect on MSNA. Data are shown as means ± SEM. * P < 0.05 versus normoxic eupnoea Campbell, & Esler, 2006) in patients with essential hypertension. This discrepancy might be explained by the smaller daily dose of losartan and smaller blood pressure reductions in the previous study (Krum et al., 2006) . We attribute sympathetic activation in our subjects to baroreflex unloading elicited by losartan-induced decreases in blood pressure. Changes in MSNA and MAP were moderately correlated (r = −0.67) in losartan-treated subjects, but not in allopurinol-or placebo-treated subjects (r = −0.11 and −0.07). Although MSNA increased significantly in losartan-treated subjects, between-group differences were insignificant, perhaps owing to lack of statistical power. We cannot rule out this possibility; nevertheless, losartaninduced increases in baseline MSNA might have clinical importance.
Methodological considerations
Our blood pressure measurements were made immediately before laboratory tests of chemoreflex and vascular function. They are averages of three to five measurements made at 1 min intervals after ≥45 min of supine rest. Further studies are required to determine the effects of allopurinol and losartan on 24 h blood pressure profiles.
We did not have the scheduling flexibility to test female subjects at a standardized phase of the menstrual cycle. Ventilation , separated by sex, in the three treatment groups. In female subjects, baseline FVC was significantly increased by allopurinol but unaffected by losartan and placebo treatments (repeated-measures ANOVA P = 0.009). Baseline FVC did not change with any treatment in male subjects. Bottom panel shows initial and final values for normoxic cerebral vascular conductance (CVC), separated by sex, in the three treatment groups. The CVC did not change with any treatment, and subgroup analysis revealed no sex differences. Data are shown as means + SEM Fu, Minson, & Joyner, 2013; Minson, Halliwill, Young, & Joyner, 2000) and ventilatory (MacNutt et al., 2012; Schoene, Robertson, Pierson, & Peterson, 1981) and sympathoexcitatory (Usselman et al., 2015) responses to hypoxia vary throughout the menstrual cycle, whereas vascular responses to hypoxia remain stable (Minson et al., 2000) . Thus, hormone fluctuations might have obscured or amplified the effects of treatment on ventilation and MSNA in our premenopausal subjects (47% of female participants), but it is unlikely that they affected vascular conductance. Allopurinol-induced increases in forearm vascular conductance were comparable in pre-and postmenopausal females, as were the effects of drug treatment on all other ventilatory and neurocirculatory variables. Shoemaker, & Bondar, 2000) , and a strong correlation between middle cerebral artery velocity and volume flow has been demonstrated (Kirkham et al., 1986) .
We recorded sympathetic outflow to vascular structures in the leg. This neural discharge is representative of sympathetic outflow to skeletal muscle vascular beds throughout the body (Rea & Wallin, 1989) ; however, our findings cannot be extrapolated to other organs or vascular beds.
Conclusions
Six weeks of treatment with losartan and allopurinol lowered arterial pressure in hypertensive patients with moderate-to-severe OSA who were, on average, adherent to CPAP treatment. The effects of CPAP alone on arterial pressure are variable (Becker et al., 2003; CamposRodriguez et al., 2006; Robinson et al., 2006) and, at best, modest (Hu, Fan, Chen, Yin, & Zrenner, 2015; Sun et al., 2016) . Optimal blood pressure control in OSA often requires additional pharmacotherapy;
however, no specific class of antihypertensive agents has been judged to be superior (Ahmad, Makati, & Akbar, 2017) . We propose that both allopurinol and losartan are viable therapeutic options for patients with OSA, even those who are adequately treated with CPAP.
